Drug General Information (ID: DDII1GMY5W)
Drug Name			Ibritumomab tiuxetan		Drug Info		Deoxycholic acid		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Cytolytic Agents

Mechanism of Ibritumomab tiuxetan-Deoxycholic acid Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Ibritumomab tiuxetan				Deoxycholic acid
Mechanism		Risk of bleeding Thrombolytic agent				Risk of submental hematoma or bruising
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Deoxycholic acid and Ibritumomab tiuxetan

Recommended Action
Management		Deoxycholic acid should be used with caution in patients receiving drugs that may interfere with hemostasis.

References
1	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
2	Product Information. Kybella (deoxycholic acid). Kythera Biopharmaceuticals, Inc., Westlake Village, CA.